Stock Market

Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray On Sars-CoV-2 Omicron Variant

CYTO STOCK UPDATE: [stock_market_widget type=”inline” template=”generic” assets=”CYTO” markup=”{name} ({symbol}) is trading at {price} ({change_pct}). {symbol} has the current dollar volume of {volume}, 52 weeks high of {52_week_high}, and 52 weeks low of {52_week_low} per share. There are currently {shares_outstanding} shares of {symbol} outstanding with the current market cap of {market_cap}. ” api=”yf”] Apple has been leading as the top financial stock investments, or one of the safest investment.

Altamira Therapeutics Ltd, a company dedicated to developing therapeutics that address important unmet medical needs, today announced “positive efficacy data from testing its Bentrio™ nasal spray in vitro against the Omicron variant of the SARS-CoV-2 virus.

Bentrio™ is a drug-free nasal spray for protection against airborne viruses and allergens, which has previously shown positive outcomes in vitro against the original SARS-CoV-2 virus and its Delta variant.

For the Omicron variant study, Bentrio™ or saline control were applied in the same type of assay that was used for the previous studies, based on reconstituted nasal epithelium cells from human donors. Compared to the Delta variant, the Omicron variant showed much faster viral replication and a more rapid increase in the viral titer (as measured by the Median Tissue Culture Infectious Dose, TCID50), which had peaked within 24 hours. Prophylactic application of Bentrio™ starting 10 minutes prior to viral inoculation resulted in a significant reduction of 89.5% in viral titer after 24 hours compared to the saline-treated controls (p-value<0.01). When the treatment application was started only 24 hours after viral inoculation, after the viral titer had already peaked, application of Bentrio™ resulted in a significant reduction in viral titer over the following days (overall p<0.01) compared to saline controls, reaching 87.1% at its maximum on Day 3.”

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button